Skip Nav Destination
Long-term outcome of individuals with pure red cell aplasia and antierythropoietin antibodies in patients treated with recombinant epoetin: a follow-up report from the Research on Adverse Drug Events and Reports (RADAR) Project
Results of a phase 1 clinical trial of thalidomide in combination with fludarabine as initial therapy for patients with treatment-requiring chronic lymphocytic leukemia (CLL)
Breast cancer risk following radiotherapy for Hodgkin lymphoma: modification by other risk factors
Sequential deregulation of NK cell subset distribution and function starting in acute HIV-1 infection
JAK2 mutation 1849G>T is rare in acute leukemias but can be found in CMML, Philadelphia chromosome–negative CML, and megakaryocytic leukemia
Altered gene expression in myeloproliferative disorders correlates with activation of signaling by the V617F mutation of Jak2
The JAK2V617F activating mutation occurs in chronic myelomonocytic leukemia and acute myeloid leukemia, but not in acute lymphoblastic leukemia or chronic lymphocytic leukemia
Durable hematologic complete response and suppression of HTLV-1 viral load following alemtuzumab in zidovudine/IFN-α–refractory adult T-cell leukemia
Cell of origin, germinal center versus nongerminal center, determined by immunohistochemistry on tissue microarray, does not correlate with outcome in patients with relapsed and refractory DLBCL
Severe imbalance of IL-18/IL-18BP in patients with secondary hemophagocytic syndrome
Relationship of patient survival and chromosome anomalies detected in metaphase and/or interphase cells at diagnosis of myeloma
Prevalence, clinical profile, and prognosis of NPM mutations in AML with normal karyotype
No evidence that FLT3 status should be considered as an indicator for transplantation in acute myeloid leukemia (AML): an analysis of 1135 patients, excluding acute promyelocytic leukemia, from the UK MRC AML10 and 12 trials
Issue Archive
Table of Contents
INSIDE BLOOD
EDITORIALS
CLINICAL TRIALS AND OBSERVATIONS
Long-term outcome of individuals with pure red cell aplasia and antierythropoietin antibodies in patients treated with recombinant epoetin: a follow-up report from the Research on Adverse Drug Events and Reports (RADAR) Project
Clinical Trials & Observations
Charles L. Bennett,Denis Cournoyer,Kenneth R. Carson,Jerome Rossert,Stefano Luminari,Andrew M. Evens,Francesco Locatelli,Steven M. Belknap,June M. McKoy,E. Alison Lyons,Benjamin Kim,Rishi Sharma,Stacey Costello,Edwin B. Toffelmire,George A. Wells,Hans A. Messner,Paul R. Yarnold,Steven M. Trifilio,Dennis W. Raisch,Timothy M. Kuzel,Allen Nissenson,Lay-Cheng Lim,Martin S. Tallman,Nicole Casadevall
Results of a phase 1 clinical trial of thalidomide in combination with fludarabine as initial therapy for patients with treatment-requiring chronic lymphocytic leukemia (CLL)
Clinical Trials & Observations
Asher Chanan-Khan,Kena C. Miller,Kenichi Takeshita,Alexandra Koryzna,Kathleen Donohue,Zale P. Bernstein,Alice Mohr,Donald Klippenstein,Paul Wallace,Jerome B. Zeldis,Christine Berger,Myron S. Czuczman
Breast cancer risk following radiotherapy for Hodgkin lymphoma: modification by other risk factors
Clinical Trials & Observations
Deirdre A. Hill,Ethel Gilbert,Graça M. Dores,Mary Gospodarowicz,Flora E. van Leeuwen,Eric Holowaty,Bengt Glimelius,Michael Andersson,Tom Wiklund,Charles F. Lynch,Mars van't Veer,Hans Storm,Eero Pukkala,Marilyn Stovall,Rochelle E. Curtis,James M. Allan,John D. Boice,Lois B. Travis
Sequential deregulation of NK cell subset distribution and function starting in acute HIV-1 infection
Clinical Trials & Observations
Brief Report
Galit Alter,Nickolas Teigen,Benjamin T. Davis,Marylyn M. Addo,Todd J. Suscovich,Michael T. Waring,Hendrik Streeck,Mary N. Johnston,Kyle D. Staller,M. Tauheed Zaman,Xu G. Yu,Mathias Lichterfeld,Nesli Basgoz,Eric S. Rosenberg,Marcus Altfeld
JAK2 mutation 1849G>T is rare in acute leukemias but can be found in CMML, Philadelphia chromosome–negative CML, and megakaryocytic leukemia
Clinical Trials & Observations
Brief Report
Jaroslav Jelinek,Yasuhiro Oki,Vazganush Gharibyan,Carlos Bueso-Ramos,Josef T. Prchal,Srdan Verstovsek,Miloslav Beran,Elihu Estey,Hagop M. Kantarjian,Jean-Pierre J. Issa
Altered gene expression in myeloproliferative disorders correlates with activation of signaling by the V617F mutation of Jak2
Clinical Trials & Observations
Brief Report
Robert Kralovics,Soon-Siong Teo,Andreas S. Buser,Martin Brutsche,Ralph Tiedt,Andre Tichelli,Francesco Passamonti,Daniela Pietra,Mario Cazzola,Radek C. Skoda
The JAK2V617F activating mutation occurs in chronic myelomonocytic leukemia and acute myeloid leukemia, but not in acute lymphoblastic leukemia or chronic lymphocytic leukemia
Clinical Trials & Observations
Brief Report
Ross L. Levine,Marc Loriaux,Brian J. P. Huntly,Mignon L. Loh,Miroslav Beran,Eric Stoffregen,Roland Berger,Jennifer J. Clark,Stephanie G. Willis,Kim T. Nguyen,Nikki J. Flores,Elihu Estey,Norbert Gattermann,Scott Armstrong,A. Thomas Look,James D. Griffin,Olivier A. Bernard,Michael C. Heinrich,D. Gary Gilliland,Brian Druker,Michael W. N. Deininger
Durable hematologic complete response and suppression of HTLV-1 viral load following alemtuzumab in zidovudine/IFN-α–refractory adult T-cell leukemia
Clinical Trials & Observations
Brief Report
Andrew Mone,Shannon Puhalla,Susan Whitman,Robert A. Baiocchi,Julio Cruz,Tamara Vukosavljevic,Amy Banks,Charles F. Eisenbeis,John C. Byrd,Michael A. Caligiuri,Pierluigi Porcu
Cell of origin, germinal center versus nongerminal center, determined by immunohistochemistry on tissue microarray, does not correlate with outcome in patients with relapsed and refractory DLBCL
Clinical Trials & Observations
Brief Report
Craig H. Moskowitz,Andrew D. Zelenetz,Tarun Kewalramani,Paul Hamlin,Simone Lessac-Chenen,Jane Houldsworth,Adam Olshen,Raju Chaganti,Stephen Nimer,Julie Teruya-Feldstein
GENE THERAPY
HEMATOPOIESIS
HEMOSTASIS, THROMBOSIS, AND VASCULAR BIOLOGY
IMMUNOBIOLOGY
Distinct roles for the NF-κB1 and c-Rel transcription factors in the differentiation and survival of plasmacytoid and conventional dendritic cells activated by TLR-9 signals
Meredith O'Keeffe,Raelene J. Grumont,Hubertus Hochrein,Martina Fuchsberger,Raffi Gugasyan,David Vremec,Ken Shortman,Steve Gerondakis
Severe imbalance of IL-18/IL-18BP in patients with secondary hemophagocytic syndrome
Clinical Trials & Observations
Karin Mazodier,Valérie Marin,Daniela Novick,Catherine Farnarier,Stéphane Robitail,Nicolas Schleinitz,Véronique Veit,Pascale Paul,Menachem Rubinstein,Charles A. Dinarello,Jean-Robert Harlé,Gilles Kaplanski
Potential approach to immunotherapy of chronic lymphocytic leukemia (CLL): enhanced immunogenicity of CLL cells via infection with vectors encoding for multiple costimulatory molecules
Claudia Palena,Kenneth A. Foon,Dennis Panicali,Alicia Gómez Yafal,Jarasvech Chinsangaram,James W. Hodge,Jeffrey Schlom,Kwong Y. Tsang
NEOPLASIA
In vitro profiling of the sensitivity of pediatric leukemia cells to tipifarnib: identification of T-cell ALL and FAB M5 AML as the most sensitive subsets
Bianca F. Goemans,Christian M. Zwaan,Amy Harlow,Anne H. Loonen,Brenda E. S. Gibson,Karel Hählen,Dirk Reinhardt,Ursula Creutzig,Michael C. Heinrich,Gertjan J. L. Kaspers
Relationship of patient survival and chromosome anomalies detected in metaphase and/or interphase cells at diagnosis of myeloma
Clinical Trials & Observations
Gordon W. Dewald,Terry Therneau,Dirk Larson,You Kyoung Lee,Stephanie Fink,Stephanie Smoley,Sarah Paternoster,Adewale Adeyinka,Rhett Ketterling,Daniel L. Van Dyke,Rafael Fonseca,Robert Kyle
Immunoglobulin light chain repertoire in chronic lymphocytic leukemia
Kostas Stamatopoulos,Chrysoula Belessi,Anastasia Hadzidimitriou,Tatjana Smilevska,Evangelia Kalagiakou,Katerina Hatzi,Niki Stavroyianni,Anastasia Athanasiadou,Aliki Tsompanakou,Theodora Papadaki,Garyfallia Kokkini,George Paterakis,Riad Saloum,Nikolaos Laoutaris,Achilles Anagnostopoulos,Athanasios Fassas
Nongenotoxic activation of the p53 pathway as a therapeutic strategy for multiple myeloma
Thorsten Stühmer,Manik Chatterjee,Martin Hildebrandt,Pia Herrmann,Hella Gollasch,Christian Gerecke,Sebastian Theurich,Luisa Cigliano,Rudolf A. Manz,Peter T. Daniel,Kurt Bommert,Lyubomir T. Vassilev,Ralf C. Bargou
Prevalence, clinical profile, and prognosis of NPM mutations in AML with normal karyotype
Clinical Trials & Observations
Brief Report
Nicolas Boissel,Aline Renneville,Valeria Biggio,Nathalie Philippe,Xavier Thomas,Jean-Michel Cayuela,Christine Terre,Isabelle Tigaud,Sylvie Castaigne,Emmanuel Raffoux,Stephane De Botton,Pierre Fenaux,Herve Dombret,Claude Preudhomme,for the Acute Leukemia French Association (ALFA)
RED CELLS
STEM CELLS IN HEMATOLOGY
TRANSPLANTATION
No evidence that FLT3 status should be considered as an indicator for transplantation in acute myeloid leukemia (AML): an analysis of 1135 patients, excluding acute promyelocytic leukemia, from the UK MRC AML10 and 12 trials
Clinical Trials & Observations
Rosemary E. Gale,Robert Hills,Panagiotis D. Kottaridis,Sivatharsini Srirangan,Keith Wheatley,Alan K. Burnett,David C. Linch
The antileukemia effect of HLA-matched NK and NK-T cells in chronic myelogenous leukemia involves NKG2D–target-cell interactions
Giuseppe Sconocchia,Michelle Lau,Maurizio Provenzano,Katayoun Rezvani,Wachanan Wongsena,Hiroshi Fujiwara,Nancy Hensel,Jos Melenhorst,Jonming Li,Soldano Ferrone,A. John Barrett
CORRESPONDENCE
-
Cover Image
Cover Image
![issue cover]()
Advertisement intended for health care professionals
Email alerts
Advertisement intended for health care professionals
